Surrozen (NASDAQ:SRZN) & Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrast

Surrozen (NASDAQ:SRZN) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Analyst Ratings

This is a summary of recent ratings and target prices for Surrozen and Vigil Neuroscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	0	0	0	0	0.00
Vigil Neuroscience	1	0	4	0	2.60

Vigil Neuroscience has a consensus price target of $16.60, indicating a potential upside of 572.06%. Given Vigil Neuroscience’s stronger consensus rating and higher possible upside, analysts clearly believe Vigil Neuroscience is more favorable than Surrozen.

Valuation & Earnings

This table compares Surrozen and Vigil Neuroscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$12.50 million	3.17	-$43.04 million	N/A	N/A
Vigil Neuroscience	N/A	N/A	-$82.64 million	($2.06)	-1.20

Surrozen has higher revenue and earnings than Vigil Neuroscience.

Profitability

This table compares Surrozen and Vigil Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	N/A	-120.51%	-54.68%
Vigil Neuroscience	N/A	-83.89%	-65.34%

Risk & Volatility

Surrozen has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Institutional and Insider Ownership

66.6% of Surrozen shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 43.5% of Surrozen shares are held by insiders. Comparatively, 33.0% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Vigil Neuroscience beats Surrozen on 6 of the 10 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Vigil Neuroscience

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.